COST

922.22

-0.08%↓

146.7

+0.49%↑

70.59

+2.22%↑

153.11

+2.22%↑

PEP

143

+1.05%↑

COST

922.22

-0.08%↓

146.7

+0.49%↑

70.59

+2.22%↑

153.11

+2.22%↑

PEP

143

+1.05%↑

COST

922.22

-0.08%↓

146.7

+0.49%↑

70.59

+2.22%↑

153.11

+2.22%↑

PEP

143

+1.05%↑

COST

922.22

-0.08%↓

146.7

+0.49%↑

70.59

+2.22%↑

153.11

+2.22%↑

PEP

143

+1.05%↑

COST

922.22

-0.08%↓

146.7

+0.49%↑

70.59

+2.22%↑

153.11

+2.22%↑

PEP

143

+1.05%↑

Home・Aktien・Lifecore Biomedical Inc

Lifecore Biomedical Inc

Geschlossen

BrancheKonsumgüter defensiv

6.84 3.64

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

6.39

Max

7.09

Schlüsselkennzahlen
By Trading Economics
Einkommen	14M -1.1M
Verkäufe	1.3M 36M
EPS	-0.253
Gewinnspanne	-3.147
Angestellte	406

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	11M 237M
Vorheriger Eröffnungskurs	3.2
Vorheriger Schlusskurs	6.84

Nachrichtenstimmung

By Acuity

50%

68 / 148 Ranking in Consumer defensive

Lifecore Biomedical Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

7. Nov. 2025, 21:06 UTC

Wichtige Markttreiber

JBS Down After Trump Calls for Probe into Meat-Packing Companies

7. Nov. 2025, 22:36 UTC

Ergebnisse

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

7. Nov. 2025, 22:22 UTC

Ergebnisse

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

7. Nov. 2025, 22:03 UTC

Ergebnisse

Constellation Software 3Q Rev $2.95B >CSU.T

7. Nov. 2025, 22:03 UTC

Ergebnisse

Constellation Software 3Q Net $210M >CSU.T

7. Nov. 2025, 22:03 UTC

Ergebnisse

Constellation Software 3Q EPS $9.89 >CSU.T

7. Nov. 2025, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

7. Nov. 2025, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

7. Nov. 2025, 20:59 UTC

Ergebnisse

Palantir's CEO Says His Earnings Were the Best Ever. They Weren't Even the Best of the Week. -- Barrons.com

7. Nov. 2025, 20:26 UTC

Market Talk

Natural U.S. Gas Futures Extend Rally to Three Weeks -- Market Talk

7. Nov. 2025, 20:22 UTC

Ergebnisse

Free-Spending Big Tech Dominates Earnings. As for the Rest: Don't Miss. -- Barrons.com

7. Nov. 2025, 20:04 UTC

Market Talk

Oil Futures Close Choppy Week With Losses -- Market Talk

7. Nov. 2025, 19:34 UTC

Market Talk

Gold Posts Small Gain for Week -- Market Talk

7. Nov. 2025, 19:31 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Prices of Gas-Fired Power Plants Have Room to Grow -- Market Talk

7. Nov. 2025, 19:17 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Tesla, Expedia, Take-Two, Block, Affirm, Sunrun, Globus Medical, JFrog, and More -- Barrons.com

7. Nov. 2025, 19:09 UTC

Ergebnisse

Wendy's Turnaround Won't Be Easy. Earnings, and the Stock, Tell the Story. -- Barrons.com

7. Nov. 2025, 19:08 UTC

Ergebnisse

KKR Defied Private-Equity Fundraising Slump in the Third Quarter -- WSJ

7. Nov. 2025, 18:31 UTC

Market Talk

U.S. Oil RIg Count Unchanged at 414 -- Market Talk

7. Nov. 2025, 17:27 UTC

Market Talk

EPA Announces New Exemptions to Biofuel Blending Rules -- Market Talk

7. Nov. 2025, 17:20 UTC

Market Talk

Eli Lilly GLP-1 Deal with Trump Administration Provides Net Boost -- Market Talk

7. Nov. 2025, 17:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

7. Nov. 2025, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

7. Nov. 2025, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

7. Nov. 2025, 17:17 UTC

Akquisitionen, Fusionen, Übernahmen

Satair Expects to Complete Purchase in Early 2026

7. Nov. 2025, 17:17 UTC

Akquisitionen, Fusionen, Übernahmen

Satair: Deal Includes Unical's and ecube's Seven Operational Sites and Offices, With Combined 2024 Rev of $298M and Headcount of 413

7. Nov. 2025, 17:15 UTC

Akquisitionen, Fusionen, Übernahmen

Airbus Unit Satair to Buy Unical Aviation From Platinum Equity

7. Nov. 2025, 17:09 UTC

Market Talk

PENN Is Falling Further Behind Competitors -- Market Talk

7. Nov. 2025, 16:49 UTC

Market Talk

Losing ESPN Partnership Will Hurt PENN -- Market Talk

7. Nov. 2025, 16:24 UTC

Market Talk

OPEC+'s Output Hike Pause Comes Amid Excess Supply, Lower Spare Capacity -- Market Talk

7. Nov. 2025, 16:17 UTC

Market Talk

Oil Market Faces Oversupply But "Glut" Might Be Overblown -- Market Talk

Peer-Vergleich

Kursveränderung

Lifecore Biomedical Inc Prognose

Rating-Konsens

By TipRanks

Buy

4 ratings

Buy

Halten

Sell

Basierend auf 4 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Lifecore Biomedical Inc – Dist abgegeben haben.

Stimmung

By Acuity

68 / 148 Ranking in Konsumgüter defensiv

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Lifecore Biomedical Inc

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of injectable grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.